
One Year at Sumitomo Chemical

Despite a variety of restrictions faced due to the impact of COVID-19, fiscal 2020 was a year in which we made steady progress on a number of projects, including the integration process for the South American crop protection business, the development of two candidate drugs acquired from the strategic alliance with Roivant, and the resolution of the completion guarantee for project financing for the Rabigh Phase II Project. It was also a year in which we continued to take steps to make both our company and society itself more sustainable, including setting up internal structures for achieving both carbon neutrality and plastic resource circulation.



Introduction to Sumitomo Chemical

Management Strategy

Creating Value through Business

Value Creation Platform

Pharmaceuticals

* The date given for each item is typically based on the date of the press release

Licensed out high-pressure polyethylene

production technology to a major

petrochemical company in Russia.

a manufacturing facility of photoresists for

advanced semiconductor processes in Osaka Works.

Sumitomo Dainippon Pharma launched

ORGOVYX[™] for the treatment of

Petrochemicals & Plastics

IT-related Chemicals

Decided to expand capacity of

advanced prostate cancer in the US.

Petrochemicals & Plastics

The completion guarantee for Rabigh Phase I project financing came to an end.

Pharmaceuticals

Established and began operations of a joint venture company for CDMO business in the field of regenerative medicine and cell therapy.

Health & Crop Sciences

Integrated the biorational-related business functions of Sumitomo Chemical Group under Valent BioSciences LLC in the US; opened a new state-of-the-art facility that integrates the headquarters of Valent U.S.A. LLC and R&D operations.

Petrochemicals & Plastics

Began examining a possible combination of a propane dehydrogenation (PDH) technology that converts propane gas into propylene, with CO₂ utilization technology in Singapore.

Pharmaceuticals

Myovant, consolidated subsidiary of Sumitomo Dainippon Pharma, and Pfizer enter into collaboration to develop and commercialize relugolix.

October November December 2021 January February March Decided to construct Established a Business Development a high-efficiency gas turbine Office for a Circular System for Plastics power generator at its Chiba Works. to accelerate the development of businesses based on its efforts towards 🛄 P64 building a circular system for plastics. Held an ESG Meeting Established the Carbon Neutral Strategy Council and the Carbon Neutral Strategy Cross-Functional Team to achieve carbon neutrality. 🛄 P60 Received CDP's highest rating in corporate climate action for 🛄 P95 the third consecutive year, and in water security action for the first time. CDP R&D CDP Accelerated joint research on methanol LIST A LIST 2020 2020 synthesis from carbon dioxide with CLIMATE WATER Shimane University. 🛄 P67